NL-OMON31249已完成3 期
An Open-Label, Multi-Centre, Extension Study, Evaluating the Long-Term Safety and Tolerability of Degarelix One-Month Dosing Regimen in Patients with Prostate Cancer Requiring Androgen Ablation Therapy - FE200486 CS21A
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- Ferring
- 入组人数
- 5
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •1. Written informed consent
- •2. Completion of FE200486 CS21 study
排除标准
- •1. Withdrawn/discontinued from FE200486 CS21 study
研究者
相似试验
进行中（未招募）
不适用
An Open-Label, Multi-Centre, Extension Study, Evaluating the Long-Term Safety and Tolerability of Degarelix One-Month Dosing Regimen in Patients with Prostate Cancer Requiring Androgen Ablation TherapyPatients with histologically proven prostate cancer of all stages in whom endocrine treatment is indicated.MedDRA version: 9.1Level: LLTClassification code 10060862Term: Prostate cancerEUCTR2006-006913-34-NLFerring Pharmaceuticals A/S568
进行中（未招募）
不适用
An Open-Label, Multi-Centre, Extension Study, Evaluating the Long-Term Safety and Tolerability of Degarelix One-Month Dosing Regimen in Patients with Prostate Cancer Requiring Androgen Ablation TherapyPatients with histologically proven prostate cancer of all stages in whom endocrine treatment is indicated.MedDRA version: 9.1Level: LLTClassification code 10060862Term: Prostate cancerEUCTR2006-006913-34-HUFerring Pharmaceuticals A/S568
进行中（未招募）
不适用
An Open-Label, Multi-Centre, Extension Study, Evaluating the Long-Term Safety and Tolerability of Degarelix One-Month Dosing Regimen in Patients with Prostate Cancer Requiring Androgen Ablation TherapyPatients with histologically proven prostate cancer of all stages in whom endocrine treatment is indicated.MedDRA version: 9.1Level: LLTClassification code 10060862Term: Prostate cancerEUCTR2006-006913-34-DEFerring Pharmaceuticals A/S568
进行中（未招募）
1 期
An Open-Label, Multi-Centre, Extension Study, Evaluating the Long-Term Safety and Tolerability of Degarelix One-Month Dosing Regimen in Patients with Prostate Cancer Requiring Androgen Ablation TherapyPatients with histologically proven prostate cancer of all stages in whom endocrine treatment is indicated.MedDRA version: 14.0 Level: PT Classification code 10060862 Term: Prostate cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2006-006913-34-GBFerring Pharmaceuticals A/S568
进行中（未招募）
1 期
An Open-Label, Multi-Centre, Extension Study, Evaluating the Long-Term Safety and Tolerability of Degarelix One-Month Dosing Regimen in Patients with Prostate Cancer Requiring Androgen Ablation Therapy.Patients with histologically proven prostate cancer of all stages in whom endocrine treatment is indicated.MedDRA version: 9.1Level: LLTClassification code 10060862Term: Prostate cancerEUCTR2006-006913-34-CZFerring Pharmaceuticals A/S557